Clinical Trial Update: Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) [Phase 3]

View source ↗

Summary

Phase 3 trial MK-3475-937 (KEYNOTE-937) evaluated pembrolizumab versus placebo as adjuvant therapy in hepatocellular carcinoma after complete radiological respo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2026-04-24